ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) FULC Comply with federal securities laws. On February 24, 2023, Fulcrum announced that “On February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally notified the Company that it had entered a full clinical lockdown on its Investigational New Drug (IND) application. for FTX-6058.” Following this announcement, the company’s stock price fell.

If you have purchased Fulcrum stock and suffered a loss on that investment, please contact Corey Holzer, Esq. atholzer@holzerlaw.comor Joshua Karr, Esq. atjkarr@holzerlaw.comcall our toll free number at (888) 508-6832 or visit our website at https://holzerlaw.com/case/fulcrum/ to discuss your legal rights.

Holzer & Holzer, LLC, an ISS Top-Rated Securities Litigation Law Firm for 2021 and 2022, dedicates its practice to vigorously representing shareholders and investors in litigation across the country, including shareholder class actions and derivatives disputes. Since its inception in 2000, Holzer & Holzer’s attorneys have played a critical role in recovering hundreds of millions of dollars for shareholders who have been victims of fraud and other corporate wrongdoing. More information about the law firm can be found on their website, www.holzerlaw.com, and on request from the company. Holzer & Holzer, LLC has paid for the distribution of this promotional communication and Corey Holzer is the attorney responsible for its content.

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll free)
holzer@holzerlaw.com